The Prognostic Significance of Elevated Serum Creatinine for the Recurrence and Progression in Superficial Bladder Tumors.
10.4111/kju.2007.48.9.927
- Author:
Jae Sang JOO
1
;
Jun Seok KIM
;
Seung Il JUNG
;
Taek Won KANG
;
Dong Deuk KWON
;
Chan CHOI
;
Kwang Sung PARK
;
Soo Bang RYU
Author Information
1. Department of Urology, Chonnam National University Medical School, Gwangju, Korea. sydad@hanmail.net
- Publication Type:Original Article
- Keywords:
Urinary bladder neoplasms;
Prognosis;
Creatinine
- MeSH:
Carcinoma in Situ;
Carcinoma, Transitional Cell;
Creatinine*;
Follow-Up Studies;
Humans;
Prognosis;
Recurrence*;
Retrospective Studies;
Urinary Bladder Neoplasms*;
Urinary Bladder*
- From:Korean Journal of Urology
2007;48(9):927-932
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: There are many prognostic indicators of bladder tumors including clinical, pathological and molecular markers based on tumor-related factors. This study was performed to evaluate the significance of an elevated level of serum creatinine for predicting progression and recurrence of superficial bladder tumors. MATERIALS AND METHODS: One hundred forty-seven patients that initially presented with a superficial bladder tumor(pTa or pT1) except for a carcinoma in situ were retrospectively analyzed according to several factors such as tumor stage, grade, size, multiplicity and serum creatinine for tumor recurrence and progression after a primary transurethral resection. RESULTS: The elevated serum creatinine group consisted of 20 patients 11 patients experienced recurrence(55.0%) and 3 patients experienced progression(15.0%). The control group consisted of 127 patients 39 patients experienced recurrence(30.7%) and 13 patients experienced progression (10.2%). The presence of an elevated level of serum creatinine and tumor multiplicity were statistically significant prognostic factors for tumor recurrence. CONCLUSIONS: These results can be helpful for predicting the prognosis of transitional cell carcinoma of the bladder and for planning therapeutic and follow-up strategies.
